{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:30:27Z","timestamp":1778517027521,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007224","name":"National Foundation for Science and Technology Development","doi-asserted-by":"publisher","award":["104.01-2023.17"],"award-info":[{"award-number":["104.01-2023.17"]}],"id":[{"id":"10.13039\/100007224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["KFRM RS-2024-00332516"],"award-info":[{"award-number":["KFRM RS-2024-00332516"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11095-025-03928-x","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T20:12:00Z","timestamp":1762891920000},"page":"2007-2027","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploration of 2-Mercaptoquinazolin-4(3H)-one Based N-Hydroxyheptanamides as Histone Deacetylase Inhibitors: Design, Synthesis, and Anticancer Bioevaluation"],"prefix":"10.1007","volume":"42","author":[{"given":"Le Thi","family":"Thao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang Kim","family":"Ngoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da Hyeon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ha Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Soon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duong Tien","family":"Anh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-203X","authenticated-orcid":false,"given":"Truong Thanh","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Bae","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen-Hai","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"3928_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216623","volume":"584","author":"R Damiescu","year":"2024","unstructured":"Damiescu R, Efferth T, Dawood M. Dysregulation of different modes of programmed cell death by epigenetic modifications and their role in cancer. Cancer Lett. 2024;584:216623.","journal-title":"Cancer Lett"},{"issue":"5","key":"3928_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.04.040","volume":"11","author":"D Wang","year":"2024","unstructured":"Wang D, et al. Epigenetics: mechanisms, potential roles, and therapeutic strategies in cancer progression. Genes Dis. 2024;11(5):101020.","journal-title":"Genes Dis"},{"issue":"1","key":"3928_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 2024;10(1):28.","journal-title":"Cell Death Discov"},{"key":"3928_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116129","volume":"265","author":"B Cheng","year":"2024","unstructured":"Cheng B, et al. Hdac-targeting epigenetic modulators for cancer immunotherapy. Eur J Med Chem. 2024;265:116129.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"3928_CR5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/cancers13040634","volume":"13","author":"R Jenke","year":"2021","unstructured":"Jenke R, et al. Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives. Cancers. 2021;13(4):634.","journal-title":"Cancers"},{"issue":"14","key":"3928_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143575","volume":"13","author":"D Karagiannis","year":"2021","unstructured":"Karagiannis D, Rampias T. HDAC inhibitors: dissecting mechanisms of action to counter tumor heterogeneity. Cancers (Basel). 2021;13(14):3575.","journal-title":"Cancers (Basel)"},{"key":"3928_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119504","volume":"277","author":"MJ Ramaiah","year":"2021","unstructured":"Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504.","journal-title":"Life Sci"},{"issue":"21","key":"3928_CR8","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1002\/cncr.34974","volume":"129","author":"R Parveen","year":"2023","unstructured":"Parveen R, Harihar D, Chatterji BP. Recent histone deacetylase inhibitors in cancer therapy. Cancer. 2023;129(21):3372\u201380.","journal-title":"Cancer"},{"issue":"22","key":"3928_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228828","volume":"21","author":"Y Luo","year":"2020","unstructured":"Luo Y, Li H. Structure-based inhibitor discovery of class I histone deacetylases (HDACs). Int J Mol Sci. 2020;21(22):8828.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"3928_CR10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/0022034511406919","volume":"90","author":"H Duncan","year":"2011","unstructured":"Duncan H, et al. HDACi: cellular effects, opportunities for restorative dentistry. J Dent Res. 2011;90(12):1377\u201388.","journal-title":"J Dent Res"},{"issue":"23","key":"3928_CR11","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.2174\/09298673113209990191","volume":"21","author":"H Rajak","year":"2014","unstructured":"Rajak H, et al. A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity. Curr Med Chem. 2014;21(23):2642\u201364.","journal-title":"Curr Med Chem"},{"issue":"6749","key":"3928_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/43710","volume":"401","author":"MS Finnin","year":"1999","unstructured":"Finnin MS, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;401(6749):188\u201393.","journal-title":"Nature"},{"key":"3928_CR13","doi-asserted-by":"publisher","first-page":"112679","DOI":"10.1016\/j.ejmech.2020.112679","volume":"205","author":"W Liu","year":"2020","unstructured":"Liu W, Liang Y, Si X. Hydroxamic acid hybrids as the potential anticancer agents: an overview. Eur J Med Chem. 2020;205:112679.","journal-title":"Eur J Med Chem"},{"issue":"9","key":"3928_CR14","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/cmdc.202000934","volume":"16","author":"J Melesina","year":"2021","unstructured":"Melesina J, et al. Strategies to design selective histone deacetylase inhibitors. ChemMedChem. 2021;16(9):1336\u201359.","journal-title":"ChemMedChem"},{"key":"3928_CR15","doi-asserted-by":"publisher","first-page":"113070","DOI":"10.1016\/j.ejmech.2020.113070","volume":"213","author":"F Plescia","year":"2021","unstructured":"Plescia F, et al. 4-(3h)-quinazolinones n-3 substituted with a five membered heterocycle: a promising scaffold towards bioactive molecules. Eur J Med Chem. 2021;213:113070.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"3928_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202100399","volume":"355","author":"RM Hassan","year":"2022","unstructured":"Hassan RM, et al. Design and synthesis of novel quinazolinone-based fibrates as PPAR\u03b1 agonists with antihyperlipidemic activity. Arch Pharm. 2022;355(3):2100399.","journal-title":"Arch Pharm"},{"issue":"1","key":"3928_CR17","doi-asserted-by":"publisher","first-page":"15071","DOI":"10.1038\/ncomms15071","volume":"8","author":"FE Held","year":"2017","unstructured":"Held FE, et al. Facile access to potent antiviral quinazoline heterocycles with fluorescence properties via merging metal-free domino reactions. Nat Commun. 2017;8(1):15071.","journal-title":"Nat Commun"},{"issue":"1","key":"3928_CR18","first-page":"1","volume":"11","author":"E Jafari","year":"2016","unstructured":"Jafari E, et al. Quinazolinone and quinazoline derivatives: recent structures with potent antimicrobial and cytotoxic activities. Res Pharm Sci. 2016;11(1):1\u201314.","journal-title":"Res Pharm Sci"},{"issue":"11","key":"3928_CR19","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1016\/j.ejmech.2010.07.058","volume":"45","author":"KS Kumar","year":"2010","unstructured":"Kumar KS, et al. Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4 (3) H-ones. Eur J Med Chem. 2010;45(11):5474\u20139.","journal-title":"Eur J Med Chem"},{"key":"3928_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-511X-4-22","volume":"4","author":"FM Refaie","year":"2005","unstructured":"Refaie FM, et al. The antihyperlipidemic activities of 4 (3h) quinazolinone and two halogenated derivatives in rats. Lipids Health Dis. 2005;4:1\u201311.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"3928_CR21","first-page":"387191","volume":"2013","author":"K Vijayakumar","year":"2013","unstructured":"Vijayakumar K, Ahamed AJ, Thiruneelakandan G. Synthesis, Antimicrobial, and Anti-HIV1 Activity of Quinazoline-4 (3H)-one Derivatives. J Appl Chem. 2013;2013(1):387191.","journal-title":"J Appl Chem"},{"issue":"9","key":"3928_CR22","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1016\/j.ejmech.2010.05.040","volume":"45","author":"S Zhu","year":"2010","unstructured":"Zhu S, et al. Synthesis and evaluation of 4-quinazolinone compounds as potential antimalarial agents. Eur J Med Chem. 2010;45(9):3864\u20139.","journal-title":"Eur J Med Chem"},{"key":"3928_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116766","volume":"277","author":"C Shi","year":"2024","unstructured":"Shi C, et al. Discovery of novel 2-substituted 2, 3-dihydroquinazolin-4(1h)-one derivatives as tubulin polymerization inhibitors for anticancer therapy: the in vitro and in vivo biological evaluation. Eur J Med Chem. 2024;277:116766.","journal-title":"Eur J Med Chem"},{"issue":"5","key":"3928_CR24","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1039\/D3MD00600J","volume":"15","author":"NS O'Brien","year":"2024","unstructured":"O\u2019Brien NS, et al. 2, 3-dihydroquinazolin-4 (1 h)-ones and quinazolin-4 (3 h)-ones as broad-spectrum cytotoxic agents and their impact on tubulin polymerisation. RSC Med Chem. 2024;15(5):1686\u2013708.","journal-title":"RSC Med Chem"},{"key":"3928_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112108","volume":"190","author":"C Fan","year":"2020","unstructured":"Fan C, et al. Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition. Eur J Med Chem. 2020;190:112108.","journal-title":"Eur J Med Chem"},{"key":"3928_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejmech.2017.07.074","volume":"139","author":"Y-H Fan","year":"2017","unstructured":"Fan Y-H, et al. Design, synthesis, and biological evaluation of novel 3-substituted imidazo [1, 2-a] pyridine and quinazolin-4 (3H)-one derivatives as PI3K\u03b1 inhibitors. Eur J Med Chem. 2017;139:95\u2013106.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"3928_CR27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/pr10020384","volume":"10","author":"C Mikra","year":"2022","unstructured":"Mikra C, et al. Green process for the synthesis of 3-amino-2-methyl-quinazolin-4 (3 H)-one synthones and amides thereof: DNA photo-disruptive and molecular docking studies. Processes. 2022;10(2):384.","journal-title":"Processes"},{"key":"3928_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103202","volume":"92","author":"LC Huan","year":"2019","unstructured":"Huan LC, et al. Novel 3,4-dihydro-4-oxoquinazoline-based acetohydrazides: design, synthesis and evaluation of antitumor cytotoxicity and caspase activation activity. Bioorg Chem. 2019;92:103202.","journal-title":"Bioorg Chem"},{"issue":"1","key":"3928_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/14756366.2020.1715389","volume":"35","author":"Y Le","year":"2020","unstructured":"Le Y, et al. Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment. J Enzyme Inhib Med Chem. 2020;35(1):555\u201364.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"26","key":"3928_CR30","doi-asserted-by":"publisher","first-page":"19914","DOI":"10.1039\/C4RA11780H","volume":"5","author":"F Qiao","year":"2015","unstructured":"Qiao F, et al. Synthesis, molecular modeling, and biological evaluation of quinazoline derivatives containing the 1, 3, 4-oxadiazole scaffold as novel inhibitors of VEGFR2. RSC Adv. 2015;5(26):19914\u201323.","journal-title":"RSC Adv"},{"issue":"7","key":"3928_CR31","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1021\/acsomega.0c05870","volume":"6","author":"DT Anh","year":"2021","unstructured":"Anh DT, et al. Novel 4-oxoquinazoline-based N-hydroxypropenamides as histone deacetylase inhibitors: design, synthesis, and biological evaluation. ACS Omega. 2021;6(7):4907\u201320.","journal-title":"ACS Omega"},{"issue":"6","key":"3928_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.201800027","volume":"15","author":"DT Hieu","year":"2018","unstructured":"Hieu DT, et al. Quinazoline-based hydroxamic acids: design, synthesis, and evaluation of histone deacetylase inhibitory effects and cytotoxicity. Chem Biodivers. 2018;15(6):e1800027.","journal-title":"Chem Biodivers"},{"issue":"4","key":"3928_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.201800502","volume":"16","author":"DT Hieu","year":"2019","unstructured":"Hieu DT, et al. Quinazolin-4 (3H)-one-based hydroxamic acids: design, synthesis and evaluation of histone deacetylase inhibitory effects and cytotoxicity. Chem Biodivers. 2019;16(4):e1800502.","journal-title":"Chem Biodivers"},{"key":"3928_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bioorg.2017.12.007","volume":"76","author":"DT Hieu","year":"2018","unstructured":"Hieu DT, et al. Design, synthesis and evaluation of novel N-hydroxybenzamides\/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents. Bioorg Chem. 2018;76:258\u201367.","journal-title":"Bioorg Chem"},{"issue":"1","key":"3928_CR35","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1080\/14756366.2021.1972992","volume":"36","author":"TO Mirgany","year":"2021","unstructured":"Mirgany TO, et al. Quinazolin-4(3H)-one based potential multiple tyrosine kinase inhibitors with excellent cytotoxicity. J Enzyme Inhib Med Chem. 2021;36(1):2055\u201367.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"3928_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73171-8","volume":"14","author":"AA-H Abdel-Rahman","year":"2024","unstructured":"Abdel-Rahman AA-H, et al. Novel quinazolin-4-one based derivatives bearing 1, 2, 3-triazole and glycoside moieties as potential cytotoxic agents through dual EGFR and VEGFR-2 inhibitory activity. Sci Rep. 2024;14(1):24980.","journal-title":"Sci Rep"},{"issue":"6","key":"3928_CR37","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1080\/10406638.2023.2237632","volume":"44","author":"HB Gandham","year":"2024","unstructured":"Gandham HB, Chidara S, Mahanti S. Synthesis and evaluation of novel quinazolinone thioether linked 5-aryl-1, 2, 4-triazoles for anticancer and antimicrobial activity. Polycycl Aromat Compd. 2024;44(6):3678\u201398.","journal-title":"Polycycl Aromat Compd"},{"issue":"18","key":"3928_CR38","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1016\/j.bmcl.2014.07.070","volume":"24","author":"ST Al-Rashood","year":"2014","unstructured":"Al-Rashood ST, et al. Synthesis, biological evaluation and molecular modeling study of 2-(1, 3, 4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors. Bioorg Med Chem Lett. 2014;24(18):4557\u201367.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"3928_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13065-024-01230-2","volume":"18","author":"L Emami","year":"2024","unstructured":"Emami L, Hassani M, Mardaneh P, Zare F, Saeedi M, Emami M, et al. 6-Bromo quinazoline derivatives as cytotoxic agents: design, synthesis, molecular docking and MD simulation. BMC Chem. 2024;18(1):125. https:\/\/doi.org\/10.1186\/s13065-024-01230-2.","journal-title":"BMC Chem."},{"key":"3928_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2022.132422","volume":"1254","author":"M Hisham","year":"2022","unstructured":"Hisham M, et al. Structure-based design, synthesis and antiproliferative action of new quinazoline-4-one\/chalcone hybrids as EGFR inhibitors. J Mol Struct. 2022;1254:132422.","journal-title":"J Mol Struct"},{"key":"3928_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103422","volume":"94","author":"HA Mahdy","year":"2020","unstructured":"Mahdy HA, et al. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4 (3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg Chem. 2020;94:103422.","journal-title":"Bioorg Chem"},{"key":"3928_CR42","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S490930","author":"MM Al-Sanea","year":"2024","unstructured":"Al-Sanea MM, et al. Design, synthesis, pharmacological evaluation of quinazolin-4 (3 H)-ones bearing urea functionality as potential VEGFR-2 inhibitors. Drug Des Devel Ther. 2024. https:\/\/doi.org\/10.2147\/DDDT.S490930.","journal-title":"Drug Des Devel Ther"},{"issue":"52","key":"3928_CR43","doi-asserted-by":"publisher","first-page":"38403","DOI":"10.1039\/D4RA06694D","volume":"14","author":"AM Mohamed","year":"2024","unstructured":"Mohamed AM, et al. Design, synthesis, and antiproliferative activity of new 1, 2, 3-triazole\/quinazoline-4-one hybrids as dual EGFR\/BRAF V600E inhibitors. RSC Adv. 2024;14(52):38403\u201315.","journal-title":"RSC Adv"},{"issue":"1","key":"3928_CR44","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1080\/14756366.2022.2118735","volume":"37","author":"A Sonousi","year":"2022","unstructured":"Sonousi A, et al. Design and synthesis of novel quinazolinone-based derivatives as EGFR inhibitors with antitumor activity. J Enzyme Inhib Med Chem. 2022;37(1):2644\u201359.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"5","key":"3928_CR45","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1021\/acs.jmedchem.6b01846","volume":"60","author":"F Dai","year":"2017","unstructured":"Dai F, et al. Design, synthesis, and biological evaluation of mitochondria-targeted flavone\u2013naphthalimide\u2013polyamine conjugates with antimetastatic activity. J Med Chem. 2017;60(5):2071\u201383.","journal-title":"J Med Chem"},{"key":"3928_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejmech.2013.08.019","volume":"69","author":"Q Tang","year":"2013","unstructured":"Tang Q, et al. Design, synthesis, and structure\u2013activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents. Eur J Med Chem. 2013;69:77\u201389.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"3928_CR47","first-page":"3029","volume":"52","author":"L Wu","year":"1992","unstructured":"Wu L, et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res. 1992;52(11):3029\u201334.","journal-title":"Cancer Res"},{"issue":"16","key":"3928_CR48","doi-asserted-by":"publisher","first-page":"6110","DOI":"10.1021\/ja111104p","volume":"133","author":"R Wu","year":"2011","unstructured":"Wu R, et al. Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel. J Am Chem Soc. 2011;133(16):6110\u20133.","journal-title":"J Am Chem Soc"},{"issue":"22","key":"3928_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127537","volume":"30","author":"DT Anh","year":"2020","unstructured":"Anh DT, et al. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents. Bioorg Med Chem Lett. 2020;30(22):127537.","journal-title":"Bioorg Med Chem Lett"},{"key":"3928_CR50","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.molstruc.2015.12.007","volume":"1108","author":"M Hagar","year":"2016","unstructured":"Hagar M, et al. Synthesis, molecular structure and spectroscopic studies of some new quinazolin-4 (3H)-one derivatives; an account on the N-versus S-alkylation. J Mol Struct. 2016;1108:667\u201379.","journal-title":"J Mol Struct"},{"key":"3928_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/vjch.202300093","volume":"61","author":"LBT Thuy","year":"2023","unstructured":"Thuy LBT, et al. Synthesis and antibacterial activities of some novel hybrid compounds based on 2-mercapto-3-arylquinazolin-4 (3H)-one scaffold bearing specific coumarin. Vietnam J Chem. 2023;61:131\u20136.","journal-title":"Vietnam J Chem"},{"issue":"3","key":"3928_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2024.101971","volume":"32","author":"MA Alossaimi","year":"2024","unstructured":"Alossaimi MA, et al. Design, synthesis, molecular docking, and in vitro studies of 2-mercaptoquinazolin-4 (3H)-ones as potential anti-breast cancer agents. Saudi Pharm J. 2024;32(3):101971.","journal-title":"Saudi Pharm J"},{"issue":"7","key":"3928_CR53","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","volume":"16","author":"M Duvic","year":"2007","unstructured":"Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007;16(7):1111\u201320.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"3928_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1091581809352111","volume":"29","author":"JS Kerr","year":"2010","unstructured":"Kerr JS, et al. Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int J Toxicol. 2010;29(1):3\u201319.","journal-title":"Int J Toxicol"},{"issue":"20","key":"3928_CR55","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1021\/jm060999m","volume":"49","author":"AR Leach","year":"2006","unstructured":"Leach AR, Shoichet BK, Peishoff CE. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem. 2006;49(20):5851\u20135.","journal-title":"J Med Chem"},{"key":"3928_CR56","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejmech.2012.07.052","volume":"56","author":"MN Renn\u00f3","year":"2012","unstructured":"Renn\u00f3 MN, et al. Kinetics and docking studies of two potential new inhibitors of the nucleoside hydrolase from Leishmania donovani. Eur J Med Chem. 2012;56:301\u20137.","journal-title":"Eur J Med Chem"},{"key":"3928_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2025.118143","volume":"122","author":"TT Lan","year":"2025","unstructured":"Lan TT, Kyung HH, Duc KN, Mai TD, Su DJ, Kim J, et al. Designs, synthesis and biological evaluation of novel hydroxamic acid-derived histone deacetylase inhibitors bearing a 2-oxoindoline scaffold as potential antitumor agents. Bioorg Med Chem. 2025;122: 118143. https:\/\/doi.org\/10.1016\/j.bmc.2025.118143.","journal-title":"Bioorg Med Chem."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03928-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03928-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03928-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:03:05Z","timestamp":1765468985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03928-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3928"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03928-x","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}